Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NRx Pharmaceuticals Inc (NRXPW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: NRXPW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -70.21% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 714.61M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.55 | 52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 |
52 Weeks Range 0.04 - 0.50 | Updated Date 05/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.25 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -191.74% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 13364027 |
Shares Outstanding - | Shares Floating 13364027 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NRx Pharmaceuticals Inc
Company Overview
History and Background
NRx Pharmaceuticals, Inc., founded in 2015, focuses on developing novel therapeutics for central nervous system disorders, particularly those related to suicidal depression and PTSD. It has evolved through clinical trials and strategic partnerships.
Core Business Areas
- CNS Therapeutics Development: Focuses on developing therapies for suicidal depression and PTSD. Its lead drug candidates target these conditions.
- Collaboration and Partnerships: NRx Pharmaceuticals collaborates with other companies and research institutions to advance its drug development programs.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The organizational structure includes research and development, clinical operations, and commercialization teams.
Top Products and Market Share
Key Offerings
- NRx-101 (D-cycloserine & lurasidone): This drug is for Suicidal Treatment-Resistant Bipolar Depression (STRBD). Market share is currently nascent (as the drug is still in development), but represents a significant unmet need with few direct competitors aside from Ketamine infusions (e.g., Janssen's Spravato) and off-label alternatives.
- HTX-100 (IV ketamine): HTX-100 is an intravenous ketamine treatment, used in the treatment of depression and PTSD. Competitors include Janssen Pharmaceuticals (Spravato). No market share data available.
Market Dynamics
Industry Overview
The pharmaceutical industry is experiencing growth in the area of mental health treatments, driven by the increasing prevalence of mental health disorders and growing awareness of the need for effective therapies.
Positioning
NRx Pharmaceuticals is positioning itself as a leader in the development of innovative therapies for suicidal depression and PTSD, focusing on addressing unmet needs in these areas.
Total Addressable Market (TAM)
The TAM for depression and PTSD treatments is estimated to be in the billions of dollars. NRx Pharmaceuticals is positioned to capture a portion of this market with its novel drug candidates.
Upturn SWOT Analysis
Strengths
- Novel drug candidates targeting unmet needs
- Experienced leadership team
- Strategic partnerships
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Regulatory approval risks
Opportunities
- Growing market for mental health treatments
- Potential for breakthrough therapies
- Expansion into new indications
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JNJ
- LLY
- ALKS
Competitive Landscape
NRx Pharmaceuticals faces significant competition from larger, more established pharmaceutical companies with greater resources. NRx advantage lies in novel approach and focus on STRBD.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by clinical trial milestones and partnership agreements.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for NRx-101 and HTX-100 and securing new partnerships.
Summary
NRx Pharmaceuticals is a speculative investment, as its success hinges on clinical trial outcomes and regulatory approvals for its lead drug candidates. The company is addressing an unmet need in suicidal depression, but it faces significant competition and financial challenges. Successful development and commercialization of NRx-101 or HTX-100 would significantly boost the company's value. Investors should carefully consider the risks associated with biotechnology stocks, particularly those in the clinical stage.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, SEC reports, Industry reports, Analyst reports, Publicly available information
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a financial advisor. Market share is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRx Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-01 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.